Highlights Pooled results from two-year-long CEDAR and SEQUOIA clinical trials indicated the efficacy of abicipar (2 mg every 8 weeks) and 2 mg every 12 weeks in treating neovascular age-related macular degeneration (nAMD). Abicipar 2 mg every 8 weeks and 2 mg every 12 weeks showed reduced incidences of intraocular inflammation (IOI) events in the second year, and the results were comparable with ranibizumab (0.8% and 2.3% vs. 1.0%).
This Journal Watch discusses the study “Two-year results of the phase 3 randomized controlled study of abicipar in neovascular age-related macular degeneration” published in Ophthalmology, 2021 . Need for the study: There exists an unmet need for longer-acting medication that can reduce the treatment burden associated with anti-vascular endothelial growth factor (anti-VEGF) therapy in neovascular age-related macular degeneration. Study details Table 1.…
